NASDAQ · BRKRP
Healthcare · Medical - Devices
$405.85
Down-$11.77 (-2.82%)
Updated Oct 19, 2026, 8:48 AM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · BRKRP
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
BRKRP closed at $405.85 after 20 trading sessions, down 11.12% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $412.79 | $412.79 | $402.415 | $405.85 | 3.07K |
| Oct 15, 2026 | $406.46 | $420.18 | $406.46 | $417.62 | 1.26K |
| Oct 14, 2026 | $412.25 | $427.92 | $406.71 | $417.475 | 2.25K |
| Oct 13, 2026 | $412.80 | $417.37 | $407.65 | $417.37 | 2.19K |
| Oct 12, 2026 | $420.03 | $420.03 | $414.48 | $415.20 | 1.01K |
| Oct 9, 2026 | $431.785 | $432.88 | $431.43 | $432.85 | 334 |
| Oct 8, 2026 | $427.47 | $427.67 | $417.39 | $427.67 | 2.54K |
| Oct 7, 2026 | $431.97 | $445.53 | $425.74 | $438.15 | 4.12K |
| Oct 6, 2026 | $458.87 | $458.87 | $437.31 | $445.04 | 3.36K |
| Oct 5, 2026 | $461.94 | $468.58 | $461.94 | $466.08 | 1.26K |
| Oct 2, 2026 | $466.18 | $467.89 | $462.64 | $465.78 | 1.84K |
| Oct 1, 2026 | $471.01 | $471.01 | $452.685 | $452.685 | 8.17K |
| Sep 30, 2026 | $475.92 | $484.90 | $471.09 | $471.09 | 20.55K |
| Sep 29, 2026 | $466.77 | $471.27 | $460.08 | $470.78 | 2.32K |
| Sep 28, 2026 | $467.47 | $474.08 | $464.78 | $469.28 | 21.74K |
| Sep 25, 2026 | $472.03 | $473.91 | $465.86 | $470.52 | 2.07K |
| Sep 24, 2026 | $457.35 | $475.20 | $448.03 | $468.57 | 26.33K |
| Sep 23, 2026 | $447.09 | $448.37 | $439.16 | $439.16 | 1.78K |
| Sep 22, 2026 | $453.98 | $454.50 | $453.97 | $454.50 | 3.73K |
| Sep 21, 2026 | $452.66 | $457.31 | $452.66 | $456.63 | 8.95K |
The latest Smart Investors Daily articles mentioning BRKRP.
Company
Market Activity
Research & News
BRKRP research
Company profile and research snapshot.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Neutral | — |
| Oct 13, 2026 | TD Cowen | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 29, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 26, 2026
Bruker (NASDAQ:BRKR) CFO Gerald Herman said the company’s second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing,
SeekingAlpha · Aug 4, 2026
Bruker Corporation (BRKR) Q2 2026 Earnings Call August 4, 2026 9:00 AM EDTCompany ParticipantsJoe KostkaFrank Laukien - Chairman, CEO & PresidentGerald...
Benzinga · Aug 4, 2026
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares increased by
Yahoo · Jul 28, 2026
Bruker’s 26.8% return over the past six months has outpaced the S&P 500 by 20.6%, and its stock price has climbed to $60.45 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRKRP.
